Trillium Therapeutics (NASDAQ: TRIL) and Tetralogic Pharmaceuticals (OTCMKTS:TLOG) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.

Risk & Volatility

Trillium Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, Tetralogic Pharmaceuticals has a beta of 2.82, meaning that its share price is 182% more volatile than the S&P 500.

Insider and Institutional Ownership

47.5% of Trillium Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Tetralogic Pharmaceuticals shares are owned by institutional investors. 15.4% of Tetralogic Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Trillium Therapeutics and Tetralogic Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trillium Therapeutics N/A -248.39% -65.21%
Tetralogic Pharmaceuticals N/A N/A N/A

Valuation & Earnings

This table compares Trillium Therapeutics and Tetralogic Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Trillium Therapeutics N/A N/A -$23.96 million ($3.79) -2.74
Tetralogic Pharmaceuticals N/A N/A -$49.72 million ($1.65) -0.02

Trillium Therapeutics is trading at a lower price-to-earnings ratio than Tetralogic Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Trillium Therapeutics and Tetralogic Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trillium Therapeutics 0 0 3 0 3.00
Tetralogic Pharmaceuticals 0 0 0 0 N/A

Trillium Therapeutics presently has a consensus price target of $12.50, suggesting a potential upside of 20.19%. Given Trillium Therapeutics’ higher probable upside, equities research analysts plainly believe Trillium Therapeutics is more favorable than Tetralogic Pharmaceuticals.

Summary

Tetralogic Pharmaceuticals beats Trillium Therapeutics on 5 of the 9 factors compared between the two stocks.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

Tetralogic Pharmaceuticals Company Profile

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.

Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.